# PT-141 (Bremelanotide): What the Research Actually Found > PT-141 is a melanocortin receptor agonist studied for sexual desire and approved for one narrow use. A plain-English, fully cited reading of the published evidence. A plain-clinical reading of the preclinical work, the Phase 3 trials, and the approved label — with every number traced to its source. ## Start here PT-141 is a lab-made peptide (a short chain of amino acids, the building blocks of proteins) that switches on a set of brain receptors tied to sexual desire. Its drug name is bremelanotide. Unlike the well-known erection pills, which work in the blood vessels, PT-141 works in the brain — it turns on "melanocortin" receptors in the hypothalamus, a control hub deep in the brain [1]. In studies, this raised sexual desire rather than just blood flow [5]. One form, an injection given to premenopausal women, is FDA-approved for a single use: a diagnosis called hypoactive sexual desire disorder, meaning distressingly low desire [7]. Every other use you may read about — in men, after menopause, or for "performance" — is off-label or still experimental [1]. The benefit in trials was real but modest, and the most common downside is nausea [3]. The downsides, and what people report, are covered on [PT-141 effects](/effects). ## What is PT-141 PT-141 is a synthetic cyclic heptapeptide — a ring of seven amino acids — modeled on alpha-MSH (alpha-melanocyte-stimulating hormone), a natural signaling molecule the body makes [1]. Where alpha-MSH is broken down quickly, PT-141's ring shape makes it more stable. It is an agonist (a key that fits a lock and turns it on) at the melanocortin receptors MC3R and MC4R, which sit mostly in the central nervous system [1]. The through-line in the research is consistent: PT-141 raised sexual desire and arousal by acting centrally — in the brain — rather than peripherally on blood vessels [5]. As a [melanocortin receptor agonist](/how-it-works), it switches on receptors in the brain's desire circuitry — a single mechanistic fact that separates it from every PDE-5 inhibitor (the vascular erection drugs) and explains both its promise and its side-effect profile. ## PT-141 peptide: from gastric-juice curiosity to an approved drug PT-141 began as a research peptide derived from the melanocortin family and was developed toward the clinic by a pharmaceutical company [11]. Systemic administration produced penile erections in rats and nonhuman primates, activated hypothalamic neurons (measured by increased c-Fos, a marker of nerve-cell activity), and produced rapid, dose-dependent erectile activity in men with erectile dysfunction in early trials [1]. The female-side story matured fastest. In two identical Phase 3 randomized controlled trials — collectively called RECONNECT, enrolling 1,267 premenopausal women — bremelanotide at 1.75 mg given subcutaneously as needed produced a statistically significant improvement in sexual desire and a reduction in desire-related distress over 24 weeks [3]. That data supported FDA approval in June 2019 for hypoactive sexual desire disorder in premenopausal women [7]. ## What the literature establishes — and what it doesn't Three things are well supported. First, the mechanism is central: a neuroimaging (fMRI) study in 31 women showed that melanocortin MC4R activation increased sexual desire for up to 24 hours and changed how the brain processed erotic cues [5]. Second, the efficacy in the approved population is real but modest — the desire-score improvement averaged +0.35 on the trial's scale [3]. Third, tolerability is the practical limit: nausea was reported by roughly 40% of women over long-term use and was a leading reason people stopped [4]. What the literature does not establish: approval beyond premenopausal women, any benefit for "performance" in healthy people, or that PT-141 raises testosterone — it does not act through the hormone axis that controls testosterone [9]. The full account of the [PT-141 benefits](/benefits) measured in trials, and the detailed [PT-141 research](/research) behind each claim, sit on their own pages. ## How this site reads the evidence This is an editorial reading room, not a clinic and not a store. Each page leads with a plain-English summary, then gives the full detail with a numbered citation on every quantitative claim. Cited human-trial data is kept visibly separate from the unverified field reports people post online — those are labeled anecdotal and never presented as proof. You can trace any figure on this site to its study on the [PT-141 references](/references) page. No dose is recommended to anyone. --- A cool cathode-blue reading desk for the PT-141 (bremelanotide) record — the one approved use, the modest measured benefit, and the nausea-led tolerability cost surfaced first and traced line by line to source, with the unverified field reports held off the lit panel and labeled plainly; a quiet instrument of the evidence, not a clinic, and nothing here dosed, sourced, or sold.